Given our strategic location in the heart of Maryland’s vibrant biotech landscape, and our unique access to speciality items such as Rituxan (rituximab) and other oncolytics and injectables, Blue Door Pharma has become the “go to” distributor for many procurement officers.
Blue Door Pharma’s current customers are primarily US-based biotech companies with a general focus on pharmaceutical and biopharmaceutical research and development, and include some of the leaders in the industry, all who appreciate the value, quality, and service we provide.
Rituxan (Rituximab) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of B cells. Rituximab destroys B cells, and is therefore used to treat diseases which are characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. This includes many lymphomas, leukemias, transplant rejection, and some autoimmune disorders. Rituximab comes packaged as both 100 mg/10 mL and 500 mg/50 mL solution in a single-use vial.